Pfizer Inc. / Sanofi-Aventis (Exubera worldwide rights)

Diabetes Mellitus (Type 1 and Type 2)

$2.0B Projected peak Exubera sales (analyst consensus, never realized)

Disease Overview

Diabetes is a chronic metabolic disease in which the body cannot regulate blood glucose because of impaired insulin production (Type 1) or insulin resistance (Type 2). Many patients require multiple daily injections; needle aversion has historically been cited as a major barrier to insulin initiation, motivating decades of work on alternative delivery routes.

Competitive Landscape

At time of buyout (Jan 2006), Exubera (inhaled human insulin co-developed by Pfizer/Sanofi/Nektar) had just received FDA approval (Jan 27, 2006) and EMA approval, marketed against entrenched injectable analogs: Sanofi's Lantus (insulin glargine, the dominant basal), Novo Nordisk's NovoRapid/Levemir, and Eli Lilly's Humalog/Humulin. The thesis was that ~30-40% of insulin-naive Type 2 patients delaying initiation due to needle phobia would adopt inhaled delivery. Sanofi's decision to sell out its 50% rights for $1.3-1.4B reflected internal skepticism about Exubera's commercial trajectory; analysts at the time projected up to $2B peak sales. The product proved a catastrophic commercial failure: the bulky inhaler, restrictive labeling (smokers/COPD excluded), pulmonary monitoring requirements, and unattractive reimbursement drove just $12M in sales in the first 9 months of 2007, prompting Pfizer to withdraw Exubera in October 2007 and take a $2.8B write-off. The episode became a defining cautionary tale for novel-route insulin (later echoed by MannKind's Afrezza). Sanofi's exit, in retrospect, looked prescient.